A Multiple-Dose, Dose-Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of LY3113593 in Patients Receiving Hemodialysis
Phase of Trial: Phase I
Latest Information Update: 02 Feb 2017
At a glance
- Drugs LY 3113593 (Primary)
- Indications Renal failure
- Focus Adverse reactions
- Sponsors Eli Lilly
- 25 Jan 2017 Status changed from active, no longer recruiting to completed.
- 21 Oct 2016 Planned End Date changed from 1 Aug 2017 to 1 Oct 2016.
- 21 Oct 2016 Status changed from recruiting to active, no longer recruiting.